Fever and neutropenia in pediatric hematopoietic stem cell transplant patients

Bone Marrow Transplantation

Volumn 25, Issue 1, 2000, Pages 59-65

  Mullen, C A ^a   Nair, J ^a   Sandesh, S ^a   Chan, K W ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Bone marrow transplantation; Infection; Neutropenia; Pediatrics

Indexed keywords

BUSULFAN; CD34 ANTIGEN; CYCLOPHOSPHAMIDE; CYCLOSPORIN; GAMMA GLOBIN; GRANULOCYTE COLONY STIMULATING FACTOR; MELPHALAN; METHOTREXATE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TACROLIMUS; THIOTEPA;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOCYTIC LEUKEMIA; ADOLESCENT; ADULT; ALLOGRAFT; APLASTIC ANEMIA; ARTICLE; AUTOGRAFT; BACTEREMIA; BLOOD CULTURE; BONE MARROW; CHILD; CHRONIC MYELOID LEUKEMIA; FEVER; GRAFT VERSUS HOST REACTION; GRAM POSITIVE BACTERIUM; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HOSPITALIZATION; HUMAN; HUMAN CELL; HUNTER SYNDROME; MAJOR CLINICAL STUDY; MYELODYSPLASTIC SYNDROME; NEUTROPENIA; PERIPHERAL BLOOD STEM CELL; PRIORITY JOURNAL; REGRESSION ANALYSIS; RETROSPECTIVE STUDY; SICKLE CELL ANEMIA; SOLID TUMOR; UMBILICAL CORD BLOOD;

EID: 0033964699     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1702109     Document Type: Article

References (24)

1. Rizzo JD. Current trends in BMT. ABMTR Newslett 1998; 5: 4-10.
2. Chan KW, Petropoulos D, Choroszy M et al. High-dose sequential chemotherapy and autologous stem cell reinfusion in advanced pediatric solid tumors. Bone Marrow Transplant 1997; 20: 1039-1043.
3. Worth LL, Tran H, Petropoulos D et al. Hematopoietic stem cell transplantation for childhood myeloid malignancies after high-dose thiotepa, busulfan, and cyclophosphamide. Bone Marrow Transplant 1999; 24: 947-952.
4. Dell'Orto M, Rovelli A, Barzaghi A et al. Febrile complications in the first 100 days after bone marrow transplantation in children: a single center's experience. Ped Hematol Oncol 1997; 14: 335-347.
5. Salazar R, Solá C, Maroto P et al. Infectious complications in 126 patients treated with high-dose chemotherapy and autologous peripheral blood stem cell transplantation. Bone Marrow Transplant 1999; 23: 27-33.
6. Kolbe K, Domkin D, Derigs HG et al. Infectious complications during neutropenia subsequent to peripheral blood stem cell transplantation. Bone Marrow Transplant 1997; 19: 143-147.
7. Haahr V, Peterslund NA, Møller JK. The influence of antimicrobial prophylaxis on the microbial and clinical findings in patients after autologous bone marrow transplantation. Scand J Infect Dis 1997; 29: 623-626.
8. Mossad SB, Longworth DL, Goormastic M et al. Early infectious complications in autologous bone marrow transplantation: a review of 219 patients. Bone Marrow Transplant 1996; 18: 265-271.
9. Lew MA, Kehoe K, Ritz J et al. Ciprofloxacin versus trimethoprim/sulfamethoxazole for prophylaxis of bacterial infections in bone marrow transplant recipients: a randomized, controlled trial. J Clin Oncol 1995; 13: 239-250.
10. Krüger W, Rüssmann B, Kröger N et al. Early infections in patients undergoing bone marrow or blood stem cell transplantation - a 7 year single centre investigation of 409 cases. Bone Marrow Transplant 1999; 23: 589-597.
11. Schimpff SC. Infections in the cancer patient-diagnosis, prevention, and treatment. In: Mandell GL, Bennett JE, Dolin R (eds). Principles and Practice of Infectious Diseases, 4 edn. Churchill Livingstone: New York, 1995, pp 2666-2675.
12. Sparrelid E, Remberger M, Ringden O et al. Bacteraemia during the aplastic phase after allogeneic bone marrow transplantation is associated with early death from invasive fungal infection. Bone Marrow Transplant 1998; 22: 795-800.
13. Ringden O, Remberger M, Lönnqvist B et al. Faster neutrophil and platelet engraftment, but no differences in acute GVHD or survival, using peripheral blood stem cells from related and unrelated donors, compared to bone marrow. Bone Marrow Transplant 1998; 22: 131-136.
14. Romano V, Castagnola E, Dallorso S et al. Bloodstream infections can develop late (after day 100) and/or in the absence of neutropenia in children receiving allogeneic bone marrow transplantation. Bone Marrow Transplant 1999; 23: 271-275.
15. Rackoff WR, Gonin R, Robinson C et al. Predicting the risk of bacteremia in children with fever and neutropenia. J Clin Oncol 1996; 14: 919-924.
16. Lucas KG, Brown AE, Armstrong D et al. The identification of febrile, neutropenic children with neoplastic disease at low risk for bacteremia and complications of sepsis. Cancer 1996; 77: 791-798.
17. Raad II, Whimbey EE, Rolston KVI et al. A comparison of aztreonam plus vancomycin and imipenem plus vancomycin as initial therapy for febrile neutropenic cancer patients. Cancer 1996; 77: 1386-1394.
18. Nosanchuk JD, Sepkowitz KA, Pearse RN et al. Infectious complications of autologous hone marrow and peripheral stem cell transplantation for refractory leukemia and lymphoma. Bone Marrow Transplant 1996; 18: 355-359.
19. Rubinstein P, Carrier C, Scaradavou A et al. Outcomes among 562 recipients of placental-blood transplants from unrelated donors. New Engl J Med 1998; 339: 1565-1577.
20. Mullen CA, Petropoulos D, Roberts WM et al. Outpatient treatment of fever and neutropenia for low risk pediatric cancer patients. Cancer 1999; 86: 126-134.
21. Mullen CA, Petropoulos D, Rytting M et al. Acute reversible arthropathy in a pediatric patient with cancer treated with a short course of ciprofloxacin for febrile neutropenia. J Ped Hematol Oncol 1998; 20: 516-517.
22. Jick S. Ciprofloxacin safety in a pediatric population. Ped Infect Dis J 1997; 16: 130-133.
23. Hampel B, Hullmann R, Schmidt H. Ciprofloxacin in pediatrics: worldwide clinical experience based on compassionate use-safety report. Ped Infect Dis J 1997; 16: 127-129.
24. Hughes WT, Armstrong D, Bodey GP et al. 1997 guidelines for the use of antimicrobial agents in neutropenic patients with unexplained fever. Infectious Diseases Society of America. Clin Inject Dis 1997; 25: 551-573.